Drugs / Pegylated IFN-alpha 2b
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02447887 | Aug 2015 → Apr 2017 | renal cell carcinoma | Fox Chase Cancer Center | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT00277862 Comparator | Apr 2002 → Mar 2007 | chronic hepatitis C virus infection | Ain Shams University | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegylated IFN-alpha 2b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02447887 ↗ |